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Abstract
Background: Copeptin, a surrogate marker for arginin vasopressin production, is evaluated as an osmo-dependent stress
and inflammatory biomarker in different diseases. We investigated copeptin during the menstrual cycle and its relationship
to sex hormones, markers of subclinical inflammation and estimates of body fluid.
Methods: In 15 healthy women with regular menstrual cycles, blood was drawn on fifteen defined days of their menstrual
cycle and was assayed for copeptin, progesterone, estradiol, luteinizing hormone, high-sensitive C-reactive protein, tumor
necrosis factor-alpha and procalcitonin. Symptoms of fluid retention were assessed on each visit, and bio impedance
analysis was measured thrice to estimate body fluid changes. Mixed linear model analysis was performed to assess the
changes of copeptin across the menstrual cycle and the relationship of sex hormones, markers of subclinical inflammation
and estimates of body fluid with copeptin.
Results: Copeptin levels did not significantly change during the menstrual cycle (p = 0.16). Throughout the menstrual cycle,
changes in estradiol (p = 0.002) and in the physical premenstrual symptom score (p = 0.01) were positively related to
copeptin, but changes in other sex hormones, in markers of subclinical inflammation or in bio impedance analysis-estimated
body fluid were not (all p = ns).
Conclusion: Although changes in estradiol and the physical premenstrual symptom score appear to be related to copeptin
changes, copeptin does not significantly change during the menstrual cycle.
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Introduction
Copeptin is increasingly evaluated as a volume- and osmo-
dependent stress biomarker in different diseases. Arginin vaso-
pressin (AVP), a hypothalamic hormone with a more subtle
response to stress than cortisol [1], is difficult to measure due to its
pulsatile secretory pattern, its instability and its rapid elimination
from plasma [2,3]. Copeptin derives from the prohormone of
AVP, is secreted equimolarly, is stable in vitro [4] and can
therefore be used as its surrogate marker [5]. Copeptin is also
elevated in states of acute inflammation [1] and is being studied as
a diagnostic and prognostic marker in acute and chronic illnesses
[6]. It is therefore important to recognize possible confounding
factors.
During the menstrual cycle (MC), there are changes in
hormones involved in fluid regulation and inflammatory markers
[7–9]. Accordingly, basal AVP plasma levels apparently undergo
subtle cyclic changes, being lowest during menstruation, increasing
during the follicular phase with a peak at ovulation and dropping
subsequently during the luteal phase [8,9]. There are also
measurable changes in basal AVP levels in response to sex
hormone treatment as seen with oral contraception [10,11].
Dehydration and hypertonic saline infusion reduce the plasma
osmolality threshold required for AVP release in the luteal phase
and while taking oral contraception [12].
Body fluid can be estimated by bioimpedance analysis (BIA)
[13], and symptoms related to fluid retention may be monitored,
for example through a premenstrual symptoms score (PMS) [14].
Physiological hormonal and fluid changes suggest that copeptin
levels may vary throughout the MC. These changes could be
clinically important confounding factors if copeptin is used as a
point-of-care-tool in premenopausal women with acute or chronic
illness. Therefore, we investigated the changes of copeptin during
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the MC and its relationship to sex hormones, markers of
subclinical inflammation and estimates of body fluid, such as total
body fluid measured by BIA and physical PMS symptoms.
Methods
Ethics statement
The study adheres to the declaration of Helsinki. It was
approved by the local ethics committee in Basel, Switzerland
(EKBB ‘‘Ethikkommission beider Basel’’), and all participants
signed and received a copy of a written informed consent form
before taking part in the study.
Participants
Participants were fifteen healthy women aged 18 to 36 years
with a regular MC between 26 to 33 days and confirmed ovulation
by progesterone level on day 21 of the MC. Exclusion criteria were
intake of oral contraceptives within the past 6 months, any
medication except occasional paracetamol, smoking, diabetes,
history of premenstrual syndrome, minor illness within the
previous month. Physical exercise was restricted to no more than
3 hours weekly.
Study design, definition of MC phases, and symptoms
score
Women were studied during one complete MC. After an
overnight fast of at least 10 hours, 30 ml blood was drawn
between 0730 h and 0930 h on days 3, 5, 8–16, 18, 21, 24 and 27
of each participant’s MC. Participants completed a standardized
PMS questionnaire [14,15] at every visit. Seven MC phases were
defined by days from the LH peak: each cycle was first divided into
a follicular phase (FP) and a luteal phase (LP) by the serum LH
peak. The follicular phase was further divided into early follicular
phase (EFP, days -15 to -9 from the LH peak), midfollicular phase
(MFP, days -8 to -4), and late follicular phase (LFP, days -3 to -1).
The luteal phase was further divided into early luteal phase (ELP,
days 1–3), midluteal phase (MLP, days 4–8), and late luteal phase
(LLP, days 9–14).
During EFP, MFP and MLP, patients were weighted and BIA
was used to estimate total body fluid (BIA 101, Akern S. r. l., via
Galeotti, 3, 50136, Firenze, Italy).
PMS was calculated based on a validated 17-item daily
symptom report [14] and the factor physical symptoms score
(i.e. symptoms of fluid retention: breast swelling and edema) was
evaluated in the current analysis.
Assays
The blood was immediately centrifuged, aliquoted, and stored
at 270uC. Serum samples were assayed by batch analysis. For
progesterone, estradiol, luteinizing hormone (LH), high-sensitive
C-reactive protein (hs-CRP), tumor necrosis factor – alpha (TNF-
a) and procalcitonin, standard assays were used as mentioned
elsewhere [7].
Copeptin was measured by chemiluminescence sandwich
immunoassay (Brahms, Henningsdorf, Germany) with a lower
detection limit of the assay of 0.4 pmol/L and a functional assay
sensitivity of ,1 pmol/L (,20% interassay CV).
Statistical Analysis
STATA (version 12.1 for Windows, StataCorp LP, 4905
Lakeway Drive, College Station, TX 77845 USA) was used for
data analysis. Mean values for copeptin, sex hormone levels and
inflammatory markers and the physical symptom score were
calculated for each subject in each of the seven MC phases, also
for the descriptive analyses. Where necessary, the dependent
variable was log-transformed to achieve an approximately normal
distribution. For instance, this was the case for copeptin. Mixed
linear model analysis with compound symmetry autocorrelation
structure for repeated measurements was performed to study the
changes of copeptin, estradiol, progesterone, LH and the physical
PMS symptoms factor across the MC phases as well as the
relationship of estradiol, progesterone, LH, hs-CRP, TNF-a,
procalcitonin and physical PMS factor with copeptin (as the
Figure 1. Changes of estradiol during the menstrual cycle. All 15 participants are shown (1–15). EFP: early follicular phase. MFP: midfollicular
phase. LFP: late follicular phase. LH: surge of luteinizing hormone. ELP: early luteal phase. MLP: midluteal phase. LLP: late luteal phase.
doi:10.1371/journal.pone.0098240.g001
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dependent variable) across the different MC phases. This same
analysis was done for the relationship of copeptin with body fluid
as estimated by BIA at the EFP, MFP and MLP. In a second step,
analyses were adjusted for the different MC phases to detect
potential associations of copeptin with other parameters unex-
plained by MC-phase. We also considered models with an AR-1
autocorrelation structure which showed almost identical results
(data not shown). Differences in copeptin levels between women
who reached a LLP and those who did not were calculated using
Wilcoxon rank-sum test. In our setting of 15 women whose
copeptin levels were assessed in seven different phases across the
MC, we would have had 90% power to find a statistically
significant effect of the MC if the variance of this effect across the 7
time intervals were 0.2 times the residual variance (i.e., the
variance of log-transformed copeptin levels within subjects
unexplained by the average time effects). With a found intraclass
correlation coefficient (ICC) of 0.75 (95% confidence intervals:
0.58 to 0.88), this would imply that 75% of the total variance of
log-copeptin is explained by the subject (between-subject variabil-
ity), 5% by the average time effects and 20% by unexplained
variation within subjects. P,0.05 was considered significant.
Figure 2. Changes of progesterone during the menstrual cycle. All 15 participants are shown (1–15). EFP: early follicular phase. MFP:
midfollicular phase. LFP: late follicular phase. LH: surge of luteinizing hormone. ELP: early luteal phase. MLP: midluteal phase. LLP: late luteal phase.
doi:10.1371/journal.pone.0098240.g002
Figure 3. Changes of luteinizing hormone (LH) during the menstrual cycle. All 15 participants are shown (1–15). EFP: early follicular phase.
MFP: midfollicular phase. LFP: late follicular phase. LH: surge of luteinizing hormone. ELP: early luteal phase. MLP: midluteal phase. LLP: late luteal
phase.
doi:10.1371/journal.pone.0098240.g003
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Results
Changes during the MC
Baseline characteristics are shown in table 1. Mean cycle length
was 28.5+/22.2 days. All cycles were ovulatory as confirmed by
the peak serum progesterone levels. Estradiol, progesterone, and
LH all showed characteristic changes during the MC (all p,0.001,
Figures 1–3). Copeptin levels did not significantly change during
the MC (p= 0.16, Figure 4) with a median of 3.5 pmol/l
throughout the MC (interquartile range 2.3–4.8). When compar-
ing the different MC phases using mixed linear models, highest
copeptin levels were found in the LFP, LH phase and LLP, but
differences to the EFP were not significant (all p.0.2) and
remained within physiological limits as previously described [16]
(for detailed copeptin values during each menstrual cycle phase,
see table 2).
Physical PMS symptoms changed throughout the MC phases
(p = 0.004) and were highest in the LFP. The median values
overall of all MC phases were 0 (interquartile range 0–0.5), with
values of the highest quartile (75th percentile) being 1.25, 0.33 and
0.5 in the 3 FP, 0 in the LH phase and 0.33, 1.1 and 8.1 in the 3
LP, respectively. Total body fluid (p = 0.72) and weight (p = 0.99)
did not change between the EFP, MFP and the MLP.
None of the participants developed any clinically apparent
infection or other illness during the studied MC.
Association of copeptin with sex hormones, markers of
sublinical inflammation and estimates of body fluid
during the MC
During the MC, the changes in estradiol were positively related
to changes in copeptin levels (p = 0.002), but not changes in
Figure 4. Changes of copeptin during the menstrual cycle. All 15 participants are shown (1–15). EFP: early follicular phase. MFP: midfollicular
phase. LFP: late follicular phase. LH: surge of luteinizing hormone. ELP: early luteal phase. MLP: midluteal phase. LLP: late luteal phase.
doi:10.1371/journal.pone.0098240.g004
Table 1. Baseline characteristics.
Baseline characteristics n=15
Age (years) 30.963.3
Duration of menstrual cycle (d) 28.562.2
BMI (kg*m22) 25.464.7
Hemoglobin at baseline (g %) 13.661.2
Peak progesterone (nmol/L) 54614.6
Luteinizing hormone (LH) in the EFP (IU/L) 5.4 (2.2.–3.1)
Luteinizing hormone (LH) at LH-Surge (IU/L) 44.0 (24.4–58.2)
Estradiol (pmol/L) 4626361
Estradiol in the EFP (pmol/L) 166 (136–183)
Copeptin (pmol/L) 3.5 (2.3–4.8)
Normally distributed data are shown as mean 6SD, otherwise as median (interquartile range).
EFP: Early Follicular Phase.
doi:10.1371/journal.pone.0098240.t001
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progesterone or LH (for detailed values, see table 3). Specifically, a
change of the mean concentration of estradiol during a MC phase
by 1000 pml/L was on average related to an increase in the
geometric mean of copeptin by 22%.
Changes in hs-CRP, TNF-a or procalcitonin levels were not
related to changes in copeptin levels throughout the MC (see
table 3).
Changes in total body fluid as estimated by BIA during the
EFP, MFP and MLF or in body weight were not related to
copeptin levels (Table 3). However, physical PMS symptom
changes per MC phase were positively related to changes of
copeptin during the MC (p = 0.01). On average, a change of the
mean physical PMS symptom by 1 score was related to an
increase in the geometric mean of 15%. All these results
remained unchanged when the relationships between the other
parameters and copeptin were additionally adjusted for the
different MC phases.
Discussion
In our cohort, we did not find significant MC-related changes of
copeptin levels or any relationship to progesterone or LH, but
changes of copeptin were related to estradiol during the MC,
although the relationship was weak. Copeptin levels in the LFP
were higher than in the EFP, but differences were not significant
(p = 0.19, data not shown) and within the reported inter- and
intraindividual variance in healthy women [4].
Subtle changes of AVP itself during the MC have only been
found by those studies that measured at multiple time points, even
with a low number of study participants ranging from 6 to 14
[8,17,18]. As healthy women with estrogen–progesterone-treat-
ment were shown to have an increased risk of developing exercise-
induced hyponatremia [12], estrogen-related changes in AVP may
be of clinical relevance in patients taking oral contraception.
Our data on copeptin is therefore in accordance with the
literature on AVP, which shows that hormones implicated in fluid
regulation undergo subtle changes during the MC, appear to be
influenced by estradiol, and are highest in the follicular phase
[8,17,18], although this effect was only significant in one study [8]-
Possibly, endogenous estradiol levels of the MC are not high
enough or only elevated during a too short period of time to have a
relevant influence on copeptin levels. In a larger cohort of healthy
premenopausal women with regular MC, these subtle changes in
copeptin might become statistically significant, but changes
remained within physiological levels and were not related to body
weight or total body fluid.
We excluded subjects with premenstrual syndrome. Neverthe-
less, perceived changes of body fluid as assessed by the physical
symptoms of the PMS score (fluid retention) were significantly
Table 2. Copeptin values in the menstrual cycle.
Copeptin level (pmol/L), median (IQR) Menstrual cycle phase
3.7 (2.8–4.8) early follicular phase (EFP)
3.5 (2.7–5.2) midfollicular phase (MFP)
4.1 (2.6–5.7) late follicular phase (LFP)
3.7 (1.9–5.8) surge of luteinizing hormone (LH)
3.3 (1.9–4.4) early luteal phase (ELP)
3.4 (2.4–5.0) midluteal phase (MLP)
2.2 (1.7–6.3) late luteal phase (LLP)
Number of participants n = 15 except in LLP, which was only reached by 6 participants. The median (interquartile range) copeptin levels throughout the menstrual cycle
were lower in the 6 women who had a LLP compared to the 9 women who did not (2.7 (1.8 to 3.5) pmol/L compared to 4.1 (3.3–5.2) pmol/L, p,0.05).
doi:10.1371/journal.pone.0098240.t002
Table 3. Relationship of sex hormones, inflammatory markers and estimates of body fluid with copeptin throughout the
menstrual cycle.
Parameter Beta - coefficient (95% confidence interval) p-value
Estradiol (pmol/L) 0.0002 (0.0001–0.0003) 0.002
Progesterone (nmol/L) 20.0014 (20.0048–0.0020) 0.414
Luteinizing hormone (IU/L) 0.0015 (20.0019–0.0049) 0.385
high sensitive C-reactive Protein (mg/L) 20.02836 (20.1243–0.0675) 0.562
Tumor necrosis factor alpha (pg/mL) 0.0485 (20.0338–0.1309) 0.248
Procalcitonin (ng/L) 0.0002 (20.0102–0.0105) 0.976
Total body fluid estimate by BIA (L) 0.0271 (20.3241–0.0866) 0.372
Weight (kg) 0.0124 (20.0029–0.0276) 0.111
Physical symptoms factor of the PMS score 0.1417 (0.0333–0.2501) 0.010
Beta-coefficient quantifies the relationship between the changes of the respective parameters with changes in copeptin concentrations (pmol/L) throughout the
menstrual cycle. Copeptin concentrations were log-transformed.
BIA: bio impedance analysis.
PMS: Premenstrual symptoms score.
doi:10.1371/journal.pone.0098240.t003
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related to copeptin. However, estimates of body fluid measured by
BIA did not. This may on one hand be due to the small fluid
changes throughout the MC in healthy women, and on the other
hand due to not assessed confounding factors [19], such as
hydration status, salt intake, and a reported low validity of the BIA
measurement for predicting body fluid [20].
Although copeptin levels are elevated in inflammatory states [6],
we could not show a relationship between markers of subclinical
inflammation and copeptin levels. Subclinical changes of inflam-
matory markers may be too subtle to have an influence on
copeptin levels; furthermore, women with acute or chronic
inflammatory states were excluded from participating.
The major limitation of this study is the small number of
participants, which is in part compensated by serial hormone
measurements. Possibly, in a larger sample, subtle MC-related
changes might become apparent. However, such subtle changes
within the inter- and intraindividual variance will probably not be
of clinical importance.
Second, only six women had measurements in the LLP due to
the variability of MC length.
Third, the data are only valid for morning measurements, as
potential circadian changes of copeptin are not taken into account.
Conclusions
We did not find any significant changes of copeptin levels
during the MC in healthy regularly menstruating women,
although we found a weak relationship between estradiol and
copeptin. During the MC, subtle changes of body fluid assessed by
physical symptoms of fluid retention were related to copeptin, but
markers of subclinical inflammation were not.
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luteinizing hormone. ELP: early luteal phase. MLP: midluteal
phase. LLP: late luteal phase.
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